This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard D. Moore, MD, MHS; Terri Creagh-Kirk, MS; Jeanne Keruly, RN; Grace Link, RN; Mei-Cheng Wang, PhD; Douglas Richman, MD; Richard E. Chaisson, MD; Zidovudine Epidemiology Study Group

Arch Intern Med. 1991;151(5):981-986.

Abstract
An epidemiologic study was initiated in 1987 to evaluate the long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Data from 886 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex and CD4+ lymphocyte count less than 0.25x10⁹/L are reported. Eighteen-month survival was 67% for the cohort. Pretreatment factors associated with increased survival time included index diagnosis of AIDS-related complex, hematocrit of 0.35 or greater, CD4+ lymphocyte count of 0.15x10⁹/L or greater, high functional status, and time from diagnosis of AIDS to treatment of less than 60 days. By proportional hazards analysis, development of serious anemia was the most significant factor associated with early death. Receiving zidovudine for a high proportion of time significantly improved chances of survival even if anemia developed. Serious leukopenia occurring in 37% and serious anemia occurring in 32% of patients. Nonhematologic adverse events were uncommon and no previously unreported adverse events were seen.

(Arch Intern Med. 1991;151:981-986)

Author Affiliations
From the Departments of Medicine (Drs Moore and Chaisson and Mss Keruly and Link) and Biostatistics (Dr Wang), The Johns Hopkins University, Baltimore, Md; Department of Medicine, University of California at San Diego (Dr Richman); and Burroughs Wellcome Co, Research Triangle Park, NC (Ms Creagh-Kirk).

Footnotes
Accepted for publication September 26, 1990.

Reprint requests to The Johns Hopkins Hospital, 1830 E Monument St, Room 8059, Baltimore, MD 21205 (Dr Moore).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Challenges in the Prevention, Diagnosis, and Treatment of Malaria in Human Immunodeficiency Virus Infected Adults in Sub-Saharan Africa
Brentlinger et al.
Arch Intern Med 2007;167:1827-1836.
ABSTRACT | FULL TEXT  

Status of selected nutrients and progression of human immunodeficiency virus type 1 infection
Bogden et al.
Am. J. Clin. Nutr. 2000;72:809-815.
ABSTRACT | FULL TEXT  

Tolerability, Safety, and Acceptability of Zidovudine Prophylaxis in Health Care Workers
Forseter et al.
Arch Intern Med 1994;154:2745-2749.
ABSTRACT  

Risk Factors for Kaposi's Sarcoma in Patients With Advanced Human Immunodeficiency Virus Disease Treated With Zidovudine
Gallant et al.
Arch Intern Med 1994;154:566-572.
ABSTRACT  

Predicting the Outcomes of Human Immunodeficiency Virus Infection: How Well Are We Doing?
Rabeneck and Wray
Arch Intern Med 1993;153:2749-2755.
ABSTRACT  

Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine
Chaisson et al.
Arch Intern Med 1992;152:2009-2013.
ABSTRACT  

Zidovudine: Five Years Later
McLeod and Hammer
ANN INTERN MED 1992;117:487-501.
ABSTRACT  

Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease
Easterbrook et al.
JAMA 1991;266:2713-2718.
ABSTRACT